Skip to main content
Smart Investors Daily
AR

NASDAQ · ARPO

Aerpio Pharmaceuticals, Inc.

Healthcare · Biotechnology

$2.20

Down-$0.02 (-0.90%)

Updated Sep 17, 2026, 9:36 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
53.67M
P/E ratio
-12.86
Dividend yield
0.00%
52-week range
— – —
Volume
826.01K
Avg. volume
401.78K

Price performance

ARPO price history

1M range · 0 trading sessions · Daily adjusted prices

ARPO does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ARPO news

The latest Smart Investors Daily articles mentioning ARPO.

ARPO research

Overview

Company profile and research snapshot.

Company profile

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
ARPO recent ratings
DateFirmRatingTarget
Jul 8, 2021HC Wainwright & Co.Buy
Dec 14, 2020HC Wainwright & Co.Neutral
Aug 13, 2020HC Wainwright & Co.Neutral
Jun 25, 2020HC Wainwright & Co.Neutral
Jun 12, 2019H.C. WainwrightNeutral
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.